Expression and purification of phosphorylated and non-phosphorylated human MEK1.

Protein Expr Purif

Department of Protein Engineering and Biochemistry, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.

Published: April 2007

Kinases exist in either a high or low activity form depending on the phosphorylation state of the activating lip. These two different forms of the same kinase may adopt different conformations that affect not only activity but also inhibitor binding and the ability to crystallize the protein. Therefore, isolation of homogenous preparations of the phosphorylated and non-phosphorylated versions of a kinase is critical for accurate biophysical measurements of activity, stability and ligand binding as well as for protein crystallization. The aim of the present study is the expression, purification and characterization of recombinant human MEK1 protein in both the activated and low-activity states. A baculovirus co-expression system was developed for obtaining high levels of activated, phosphorylated human MEK1 kinase. High-Five cells were co-infected with human MEK1 virus and Raf-BXB, an untagged constitutively active version of Raf which is the activating kinase for MEK1. Unphosphorylated MEK1 was generated by treating MEK1 isolated from High-Five baculovirus expression with lambda-phosphatase. The proteins were characterized by SDS-PAGE, LC-MS, Western blotting, enzymatic activity, and circular dichroism. Previous reports of MEK1 expression and purification yielded lower levels of protein and purity. The yield using High-Five cells was 5mg/L for phosphorylated MEK1 and 10mg/L for unphosphorylated MEK1. For phosphorylated MEK1, the specific activity was 3530U/mg, the IC(50) values for the non-specific kinase inhibitors K252a and K252b were 8 and 47nM, respectively, and the IC(50) for the MEK1 non-ATP competitive inhibitor, PD0325901, was 43nM.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pep.2006.11.002DOI Listing

Publication Analysis

Top Keywords

human mek1
16
expression purification
12
mek1
12
phosphorylated non-phosphorylated
8
high-five cells
8
unphosphorylated mek1
8
phosphorylated mek1
8
phosphorylated
5
activity
5
kinase
5

Similar Publications

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma.

Biomed Pharmacother

December 2024

Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do 15588, Republic of Korea. Electronic address:

Colorectal malignancies associated with KRAS and TP53 mutations led us to investigate the effects of combination therapy targeting KRAS, MEK1, or PLK1 in colorectal cancer. MEK1 is downstream of RAS in the MAPK pathway, whereas PLK1 is a mitotic kinase of the cell cycle activated by MAPK and regulated by p53. Bioinformatics analysis revealed that patients with colorectal cancer had a high expression of MAP2K1 and PLK1.

View Article and Find Full Text PDF

Objectives: To investigate the mechanism of PHPS1 for promoting apoptosis of oral squamous cell carcinoma cells and the role of AMPK in regulating tumor angiogenesis under hypoxic conditions.

Methods: Human oral squamous cell carcinoma Ca9-22 cells cultured in hypoxic conditions (1% O) were inoculated subcutaneously in 16 nude mice, which were divided into control group and PHPS1 group (8) for treatment with 10% DMSO and 10% PHPS1 respectively. Tumor growth in the mice was monitored till 14 days after the treatment, and the xenografts were examined pathologically using HE staining.

View Article and Find Full Text PDF

Doublecortin regulates the mitochondrial-dependent apoptosis in glioma via Rho-A/Net-1/p38-MAPK signaling.

Mol Med

December 2024

Department of Neurobiology and Anatomy, Key Laboratory of Neurobiology, Xuzhou Medical University, 209, Tongshan Road, Xuzhou, 221004, China.

Doublecortin (DCX) is a microtubule-associated protein known to be a key regulator of neuronal migration and differentiation during brain development. However, the role of DCX, particularly in regulating the survival and growth of glioma cells, remains unclear. In this study, we utilized CRISPR/Cas9 technology to knock down DCX in the human glioma cell line (U251).

View Article and Find Full Text PDF

A Comprehensive Review Highlighting the Prospects of Phytonutrient Berberine as an Anticancer Agent.

J Biochem Mol Toxicol

January 2025

Department of Translational Medicine, Clinical Research Centre, Skåne University Hospital, Lund University, Malmö, Sweden.

Berberine, an isoquinoline alkaloid derived from various medicinal plants, emerges as a potential therapeutic agent against diverse human diseases. It has particularly shown notable anticancer efficacy against breast, colorectal, lung, prostate, and liver cancer. Berberine results in inhibition of cancer cell proliferation, induction of apoptosis, and suppressing angiogenesis, positioning it as a versatile, multitargeted therapeutic tool against cancer.

View Article and Find Full Text PDF

Beyond BRAF: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children.

Cancer Med

December 2024

Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.

Background: Langerhans cell histiocytosis (LCH) is the most prevalent histiocytic disorder in pediatric populations, with a highly heterogeneous clinical presentation. Currently, the correlation between clinical phenotypes and molecular alterations in childhood LCH, besides the BRAF mutation, has not been sufficiently studied.

Methods: This study presented data on 33 pediatric LCH patients treated at our center who exhibited various molecular alterations other than the BRAF mutation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!